Effect of Aspiration and Evaluation of Gastric Residuals on Intestinal Inflammation, Bleeding, and Gastrointestinal Peptide Level - 22/01/20
Abstract |
Objective |
To determine the effect of gastric residual aspiration and evaluation on preterm very low birth weight infants’ gastrointestinal function, intestinal inflammation, and gastrointestinal mucosal bleeding.
Study design |
This single-center, randomized trial compared omission of gastric residuals vs prefeed gastric residuals in 143 infants ≤32 weeks of gestation with a birthweight of ≤1250 g for 6 weeks after birth. Serum levels of gastrin and motilin were collected between 14 and 21 days of life. Stools were collected at 3 and 6 weeks of age and analyzed for calprotectin and S100A12 levels. All stools were tested for occult blood for 6 weeks.
Results |
Means for gastrin (P = .999) and motilin (P = .694) were similar between groups and there were no statistically significant differences in adjusted means for transformed calprotectin (P = .580), and S100A12 (P = .212). Both calprotectin (P = .003) and S100A12 (P = .002) increased from week 3 to week 6. The mean percentage of stools positive for occult blood (P = .888) were similar between the groups.
Conclusions |
Gastrointestinal function, intestinal inflammation, and gastrointestinal mucosal bleeding were similar whether aspiration and evaluation of gastric residuals were eliminated or not, suggesting routinely evaluating gastric residuals before every feeding may be unnecessary.
Trial registration ClinicalTrials.gov: |
NCT01863043
Le texte complet de cet article est disponible en PDF.Keywords : gastric residual, neonatal intensive care unit, very low birth weight, premature
Abbreviations : LSM, MOM, NICU, VLBW
Plan
Sponsored by the National Institute of Nursing Research (R01DK088244) who had no involvement in the (1) study design, (2) the collection, analysis, and interpretation of data, (3) the writing of the report, and (4) the decision to submit the manuscript for publication. J.N. reports a grant from Infant Bacterial Therapeutics. The other authors declare no conflicts of interest. |
Vol 217
P. 165 - février 2020 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?